Loading clinical trials...
Loading clinical trials...
This study is designed to compare the efficacy and safety of first-line icotinib treatment and first-line chemotherapy followed by maintenance treatment with icotinib.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
NCT07660627 · Esophageal Adenocarcinoma, Gastric Cancer, and more
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more
NCT06342440 · Colorectal Cancer, Colorectal Neoplasms, and more
NCT04521764 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, and more
Chinese People's Liberation Army (PLA) General Hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions